Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 348

Sort by

Sort Order Select

Journal Articles

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Blood (2025) 146 (Supplement 1): 5772.

https://doi.org/10.1182/blood-2025-5772

Published: 2025

Journal Articles

Real-world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across europe, the United States and Canada

Jens Panse, Koo Wilson, Brianne Kerr, Sam Williamson, Susanna Libby, Yasmin Taylor, Peter Hillmen, David Dingli

Blood (2025) 146 (Supplement 1): 4970.

https://doi.org/10.1182/blood-2025-4970

Published: 2025

Journal Articles

The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 2281.

https://doi.org/10.1182/blood-2025-2281

Published: 2025

Journal Articles

We're not talking about sex: Hematopoietic stem cell transplant provider practices and barriers to sexual health discussions with adolescents and young adults

Brittany Kimball, Mira Kohorst, Asmaa Ferdjallah, Anand Srinivasan, Hannah Nordhues, David Dingli, Hassan Alkhateeb, Urshila Durani

Blood (2025) 146 (Supplement 1): 2872.

https://doi.org/10.1182/blood-2025-2872

Published: 2025

Journal Articles

Navigating the complement cascade: A multicenter journey from pegcetacoplan to iptacopan in paroxysmal nocturnal hemoglobinuria

Praveena Thiagarajan, Mark Orland, Serhan Unlu, Arooj Ahmed, Carlos Bravo-Perez, Matteo D Addona, Megan Basch, Soyon Lee, Ver Bilano, Jincy Paulose, Lincy Geevarghese, Vamsi Bollu, Srinivasa Reddy Sanikommu, David Dingli, Jaroslaw Maciejewski, Carmelo Gurnari

Blood (2025) 146 (Supplement 1): 1433.

https://doi.org/10.1182/blood-2025-1433

Published: 2025

Journal Articles

Management of a real-world cohort of patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: A multi-institutional analysis

Mark Orland, Praveena Thiagarajan, Serhan Unlu, Arooj Ahmed, Carlos Bravo-Perez, Matteo D Addona, Megan Basch, Soyon Lee, Ver Bilano, Jincy Paulose, Lincy Geevarghese, Vamsi Bollu, David Dingli, Jaroslaw Maciejewski, Carmelo Gurnari

Blood (2025) 146 (Supplement 1): 1430.

https://doi.org/10.1182/blood-2025-1430

Published: 2025

Journal Articles

Real-world treatment patterns and clinical outcomes among patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan in the United States

David Dingli, Soyon Lee, Nicholas Kuypers, Jincy Paulose, Ver Bilano, Hayley Nusser, Tayler Buchan, Claire Buchan, Rachel Jaffe, Anem Waheed

Blood (2025) 146 (Supplement 1): 1429.

https://doi.org/10.1182/blood-2025-1429

Published: 2025

Journal Articles

Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia

Blood (2025) 146 (Supplement 1): 1036.

https://doi.org/10.1182/blood-2025-1036

Published: 2025

Journal Articles

Clinical, anatomic, and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis: A cohort study of 560 patients

Blood (2025) 146 (Supplement 1): 3962.

https://doi.org/10.1182/blood-2025-3962

Published: 2025

Journal Articles

Cardiac complete response in AL amyloidosis: Phenotypic characteristics, functional recovery, and survival outcomes of 63 patients

Blood (2025) 146 (Supplement 1): 3960.

https://doi.org/10.1182/blood-2025-3960

Published: 2025

Journal Articles

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 250.

https://doi.org/10.1182/blood-2025-250

Published: 2025

Journal Articles

Molecular stratification of relapse risk post-allogeneic hematopoietic stem cell transplantation in myeloid neoplasms with non-adverse risk cytogenetics

Khalid Abu-Zeinah, Anmol Baranwal, Khalil Hassan, Al Rabee Kassis, Aasiya Matin, Mehrdad Hefazi Torghabeh, Abhishek Mangaonkar, Mark Litzow, William Hogan, Mithun Shah, David Dingli, Hassan Alkhateeb

Blood (2025) 146 (Supplement 1): 6073.

https://doi.org/10.1182/blood-2025-6073

Published: 2025

Journal Articles

Upfront therapy with allogeneic hematopoietic stem cell transplantation versus DNA methyltransferase inhibitors in patients with vexas syndrome: A comparative matched cohort efficacy analysis of 39 patients

Blood (2025) 146 (Supplement 1): 981.

https://doi.org/10.1182/blood-2025-981

Published: 2025

Journal Articles

Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement

Blood (2025) 146 (Supplement 1): 2225.

https://doi.org/10.1182/blood-2025-2225

Published: 2025

Journal Articles

Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma

Blood (2025) 146 (Supplement 1): 362.

https://doi.org/10.1182/blood-2025-362

Published: 2025

Journal Articles

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

Blood (2025) 146 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2025-4585

Published: 2025

Journal Articles

Disease characteristics, treatment patterns, and outcomes of AL amyloidosis patients with high-risk FISH cytogenetics

Blood (2025) 146 (Supplement 1): 5741.

https://doi.org/10.1182/blood-2025-5741

Published: 2025

Journal Articles

Fetal hemoglobin dysregulation in inherited and acquired bone marrow failure syndromes

Blood (2025) 146 (Supplement 1): 6750.

https://doi.org/10.1182/blood-2025-6750

Published: 2025

Journal Articles

Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma - a single center prospective study

Blood (2025) 146 (Supplement 1): 715.

https://doi.org/10.1182/blood-2025-715

Published: 2025

Journal Articles

Ravulizumab demonstrates real-world effectiveness in patients with paroxysmal nocturnal hemoglobinuria: A US chart review study

David Dingli, Andrew Messali, Arpita Nag, Yogesh Patel, Maral DerSarkissian, Rose Chang, Zoey Kang, Elizabeth Griffiths

Blood (2025) 146 (Supplement 1): 8010.

https://doi.org/10.1182/blood-2025-8010

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Real-world clinical characteristics and treatment outcomes in PNH patients prescribed pegcetacoplan across europe, the United States and Canada

The SCOPE trial: A phase 2 Study of selinexor in combination with pomalidomide and dexamethasone for patients with relapsed and/or refractory multiple myeloma

We're not talking about sex: Hematopoietic stem cell transplant provider practices and barriers to sexual health discussions with adolescents and young adults

Navigating the complement cascade: A multicenter journey from pegcetacoplan to iptacopan in paroxysmal nocturnal hemoglobinuria

Management of a real-world cohort of patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan: A multi-institutional analysis

Real-world treatment patterns and clinical outcomes among patients with paroxysmal nocturnal hemoglobinuria treated with iptacopan in the United States

Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia

Clinical, anatomic, and histologic determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis: A cohort study of 560 patients

Cardiac complete response in AL amyloidosis: Phenotypic characteristics, functional recovery, and survival outcomes of 63 patients

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Molecular stratification of relapse risk post-allogeneic hematopoietic stem cell transplantation in myeloid neoplasms with non-adverse risk cytogenetics

Upfront therapy with allogeneic hematopoietic stem cell transplantation versus DNA methyltransferase inhibitors in patients with vexas syndrome: A comparative matched cohort efficacy analysis of 39 patients

Clinical course, predictors of development, and therapeutic response in multiple myeloma with central nervous system involvement

Cytogenetics-based clinical trajectories of patients with MRD negativity post autologous stem cell transplant for multiple myeloma

Real-world (RW) outcomes of newly diagnosed multiple myeloma (NDMM) patients (pts) treated with front-line daratumumab (dara), bortezomib (bor), lenalidomide (len) and dexamethasone (dex) (DVRd)

Disease characteristics, treatment patterns, and outcomes of AL amyloidosis patients with high-risk FISH cytogenetics

Fetal hemoglobin dysregulation in inherited and acquired bone marrow failure syndromes

Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma - a single center prospective study

Ravulizumab demonstrates real-world effectiveness in patients with paroxysmal nocturnal hemoglobinuria: A US chart review study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only